



## GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference

November 24, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET.

The fireside chat will be webcast live from GBT's website at [www.gbt.com](http://www.gbt.com) in the Investors section. A replay of the webcast will be archived and available for one month following the event.

### About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next-generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit [www.gbt.com](http://www.gbt.com) and follow the company on Twitter [@GBT\\_news](https://twitter.com/GBT_news).

### Contact:

Steven Immergut (media)  
650-410-3258  
[simmergut@gbt.com](mailto:simmergut@gbt.com)

Courtney Roberts (investors)  
650-351-7881  
[croberts@gbt.com](mailto:croberts@gbt.com)



Source: Global Blood Therapeutics, Inc.